Why Invo BioScience Stock Is Soaring Today
Why Invo BioScience Stock Is Soaring Today
INVO BioScience, Inc. (NASDAQ:INVO) shares are trading higher Wednesday after the company reported its fourth-quarter financial results after the market close Tuesday. Here's a look at the details.
INVO BioScience, Inc.（納斯達克股票代碼：INVO）週三股價走高，此前該公司在週二收盤後公佈了第四季度財務業績。以下是細節。
The Details:
細節：
Invo Bioscience reported $1.38 million in quarterly sales, representing a 396.15% increase over sales of $278,140 from the same period last year.
Invo Bioscience公佈的季度銷售額爲138萬美元，比去年同期的278,140美元的銷售額增長了396.15％。
The company also said it remains on-track with its goal of reaching break-even or profitability within its current operations in 2024.
該公司還表示，其目標是到2024年在當前業務中實現盈虧平衡或盈利，其目標仍在按計劃進行。
Invo BioScience said it remains committed to acquire NAYA Biosciences in an all-stock transaction. Following the closing of the Merger, the combined company is expected to operate under the name "NAYA Biosciences."
Invo BioScience表示，它仍然致力於通過全股交易收購NAYA Biosciences。合併完成後，合併後的公司預計將以 “NAYA Biosciences” 的名義運營。
"We continue to execute on our plan to capture a greater share of the total fertility cycle revenue and profit through the transformation of INVO into an innovative healthcare services company, driven by our existing INVO Centers and recently acquired Wisconsin-based IVF Center," commented Steve Shum, CEO of Invo.
Invo首席執行官史蒂夫·舒姆評論說：“在我們現有的INVO中心和最近收購的威斯康星州試管嬰兒中心的推動下，我們將繼續執行我們的計劃，通過將INVO轉型爲一家創新的醫療服務公司，在整個生育週期收入和利潤中獲得更大的份額。”
Related News: What's Going On With AMC Entertainment Stock?
相關新聞：AMC 娛樂股票怎麼了？
INVO Stock Prediction 2024:
2024 年 INVO 股票預測：
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
華爾街內外的股票研究分析師通常使用收益增長和基礎研究作爲估值和預測的一種形式。但是，許多交易者將技術分析作爲形成股價走勢預測模型的一種方式。
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at INVO Bioscience , an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For INVO Bioscience, the 200-day moving average sits at $1.49, according to Benzinga Pro, which is below the current price of $2.59. For more on charts and trend lines, see a description here.
一些投資者通過趨勢來幫助預測他們認爲股票在未來某個時刻的交易走向。從INVO Bioscience來看，投資者可以使用移動平均線和趨勢線對股票的長期前景進行評估。如果他們認爲股票將保持在移動平均線上方（許多人認爲這是一個看漲信號），他們可以使用趨勢線將這種趨勢推斷到未來。根據Benzinga Pro的數據，INVO Bioscience的200天移動平均線爲1.49美元，低於目前的2.59美元。有關圖表和趨勢線的更多信息，請參閱此處的描述。
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
交易者認爲，當股票高於其移動平均線時，這是一個普遍看漲的信號，而當它跌破移動平均線時，則是一個更加消極的信號。投資者可以使用趨勢線做出有根據的猜測，如果情況保持穩定，股票以後可以在哪裏交易。
INVO Price Action: According to Benzinga Pro, Invo BioScience shares are up 264% at $2.77 at the time of publication Wednesday.
INVO價格走勢：根據Benzinga Pro的數據，Invo BioScience的股價在週三發佈時上漲了264％，至2.77美元。
譯文內容由第三人軟體翻譯。